Efficacy of Carrilizumab Combined with Anrotinib in Patients with Advanced Esophageal Squamous Cell Carcinoma and Its Effect on Immune Function
Objective To analyze the clinical effect of carrilizumab combined with anrotinib in patients with advanced e-sophageal squamous cell carcinoma.Methods A total of 65 patients with advanced esophageal squamous cell carcinoma were randomly divided into the control group(n=32)and the observation group(n=33).The control group was treated with tegafur combined with anrotinib for 21 days as a course of treatment,and the observation group was treated with carrilizumab combined with anrotinib for 21 days as a course of treatment,and both groups were treated for 4 consecutive courses of treatment.After treat-ment,the short-term efficacy,serum tumor marker levels,immune function,and the occurrence of adverse reactions were evaluated in both groups.Results The disease control rate of observation group(84.85％)was significantly enhanced compared with con-trol group(59.38％)(P＜0.05).After treatment,the expression of serum CEA,CA19-9,CA125,and SCC levels in 2 groups were decreased,and the levels of the above indexes in the observation group were significantly lower than those in the control group(P＜0.001).After treatment,the levels of CD3+,CD4+,and CD4+/CD8+were increased,while the level of CD8+was decreased,and the changes of the above indexes in the observation group were more significant than those in the control group(P＜0.01).There was no statistical significance in the incidence of hypertension,elevated transaminase,decreased appetite,fatigue,and capil-lary hyperplasia between 2 groups(P＞0.05).The incidences of granulocytopenia and thrombocytopenia in observation group were significantly declined compared with control group(P＜0.01).Conclusion Carrellizumab combined with anrotinib could signifi-cantly reduce the level of serum tumor markers,improve the immune function of patients,and improve clinical efficacy with high safety,which is worthy of clinical promotion.
万方数据
维普
